Digitoxin medication and cancer; case control and internal dose-response studies
about
Monosaccharide digitoxin derivative sensitize human non-small cell lung cancer cells to anoikis through Mcl-1 proteasomal degradationRepurposing of approved cardiovascular drugsCardiac glycosides use and the risk of lung cancer: a nested case-control studyTrial watch: Cardiac glycosides and cancer therapyCardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies.Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth.Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis.Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis.Reduction of Na/K-ATPase affects cardiac remodeling and increases c-kit cell abundance in partial nephrectomized mice.Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studiesEx vivo activity of cardiac glycosides in acute leukaemia.Recent advances in drug repositioning for the discovery of new anticancer drugsEnhancing the anticancer properties of cardiac glycosides by neoglycorandomizationHypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheresHuman breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells.A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment.Helveticoside is a biologically active component of the seed extract of Descurainia sophia and induces reciprocal gene regulation in A549 human lung cancer cells.Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.Critical role of the α1-Na(+), K(+)-ATPase subunit in insensitivity of rodent cells to cytotoxic action of ouabain.Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth.Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved.The mechanisms of chansu in inducing efficient apoptosis in colon cancer cells.Digitoxin induces apoptosis in cancer cells by inhibiting nuclear factor of activated T-cells-driven c-MYC expression.Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control studyCinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells.Reevesioside A, a cardenolide glycoside, induces anticancer activity against human hormone-refractory prostate cancers through suppression of c-myc expression and induction of G1 arrest of the cell cycle.Is digoxin use for cardiovascular disease associated with risk of prostate cancer?Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1Anticancer steroids: linking natural and semi-synthetic compounds.Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials.Peruvoside, a Cardiac Glycoside, Induces Primitive Myeloid Leukemia Cell Death.Analysis of proliferation and apoptotic induction by 20 steroid glycosides in 143B osteosarcoma cells in vitro.Digitalis Use and the Risk of Breast Cancer: A Systematic Review and Meta-Analysis.A hearty solution for acute myeloid leukemia.Na⁺i,K⁺i-Dependent and -Independent Signaling Triggered by Cardiotonic Steroids: Facts and Artifacts.Na/K Pump and Beyond: Na/K-ATPase as a Modulator of Apoptosis and Autophagy.Digitoxin analogues with improved anticytomegalovirus activity.Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition.Use of cardiac glycosides and risk of glioma.In vitro propagation and production of cardiotonic glycosides in shoot cultures of Digitalis purpurea L. by elicitation and precursor feeding.
P2860
Q23923209-95F03663-A56C-469A-AC44-1ABE8F0C4861Q28074453-21C94849-BCEA-4611-B485-70B86A038383Q28392316-0120F0D1-61E6-4C85-9236-61016441558BQ28395830-2B7198C0-875C-4906-B5DA-26BDB6025C8FQ30241045-0ECF806E-A7A3-4DC8-9955-5A06651E2A64Q33385608-2B79A741-48A6-4B9F-B7DB-3004CF6A3106Q33519074-8A0313C7-7DD6-498A-AF20-AB05871C7DCCQ33566322-A6286ECC-EFA6-4CF1-ADFA-47C786E3A08BQ33764626-28CD7721-2771-4C8F-8A8E-9CB0D61C4F05Q33773092-9C6D3D8E-415B-40DF-B6FE-54BED69F46EDQ33796670-F8CCC897-5B93-40D6-91A9-BC6E1B633800Q33845068-C6DAEE09-3C28-49CA-B88F-6AFFA312B496Q33933859-449AF96F-30A5-469F-88A4-4C2D14604ECAQ34087018-D0F58CE7-C0D0-48E5-868B-EB373482DC2BQ35071149-8125BED0-EC84-45CF-A36F-CB7D78DC2AF7Q35581883-A1A39670-21E2-40E6-8E6F-151C08D7B80AQ36073799-3DCF80A5-C23C-42F2-9649-353CFA99DB5EQ36172394-1D2632C6-2626-4937-9D14-6CEB49FDF268Q36367538-FE1D0759-2162-4357-8046-B133EB126C0AQ36817975-9091242D-3B3F-4307-870A-51D85A88394EQ36897343-F769C8C8-27A2-4563-B8AB-2DB58408BF0FQ36931329-F3F61912-5AC3-4FDC-BAFC-F8CC9D0FACA3Q37006006-63D62001-5867-49A7-A9B5-CEC1CF262629Q37131343-28A19D54-9D94-4B92-9C60-3E43BC53CD8BQ37301710-A4CA6461-8CFE-4110-8D46-C868C5ED134EQ37521136-A0B85C18-D306-42E9-BE36-F1D3D7394B1EQ37604348-479B1D0B-8E47-4CDE-92FE-E24A897B5537Q37626561-258A3CC5-53F0-4EFA-B3D0-04F3B903F661Q38059807-C3C91183-B731-4E57-A133-F5E08C1C7A71Q38113122-DEB3F9CA-C827-4313-9EBB-A7EED950209FQ38775646-0FE39BE2-38F8-4B91-BB91-85BEFB156260Q38841438-3B347C67-0976-43DC-A306-1C7D8D066FCAQ39107268-E51F6D23-C831-4AA6-BAE5-1D854C13F62DQ39234420-7FB93B63-2633-4E9D-A6AF-B6B9CE455DA2Q39248982-DB3904BC-8227-4ECE-B136-CB680D9DB265Q39254499-A332C56E-0FA0-4174-B23A-33AC06205465Q39781732-543F93A6-B1A2-4DD8-A79C-EA786BFAF38EQ39812929-DCB73862-64E5-4CF7-9B34-43DB6DEA2074Q40154465-E5B00B16-B3D2-4A85-AD38-8BB4E5221CC3Q46240197-DA351822-6EE4-4760-B191-97C60EE84145
P2860
Digitoxin medication and cancer; case control and internal dose-response studies
description
2001 nî lūn-bûn
@nan
2001 թուականին հրատարակուած գիտական յօդուած
@hyw
2001 թվականին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Digitoxin medication and cancer; case control and internal dose-response studies
@ast
Digitoxin medication and cancer; case control and internal dose-response studies
@en
Digitoxin medication and cancer; case control and internal dose-response studies
@en-gb
Digitoxin medication and cancer; case control and internal dose-response studies
@nl
type
label
Digitoxin medication and cancer; case control and internal dose-response studies
@ast
Digitoxin medication and cancer; case control and internal dose-response studies
@en
Digitoxin medication and cancer; case control and internal dose-response studies
@en-gb
Digitoxin medication and cancer; case control and internal dose-response studies
@nl
prefLabel
Digitoxin medication and cancer; case control and internal dose-response studies
@ast
Digitoxin medication and cancer; case control and internal dose-response studies
@en
Digitoxin medication and cancer; case control and internal dose-response studies
@en-gb
Digitoxin medication and cancer; case control and internal dose-response studies
@nl
P2093
P2860
P3181
P356
P1433
P1476
Digitoxin medication and cancer; case control and internal dose-response studies
@en
P2093
P2860
P2888
P3181
P356
10.1186/1471-2407-1-11
P407
P50
P577
2001-01-01T00:00:00Z
P5875
P6179
1041037575